Laboratory Testing in Psychiatry (August)

Date of Issue: 08/01/2007 | Volume: 5 | Number: 8

Issue Links:Learning Objectives | Editorial Information

Teaser to be posted soon.

In This Issue

Article

Screening Labs for New Patients: Are they Useful?

Topics: Laboratory Testing in Psychiatry

In psychiatry, we typically order screening labs on new patients for a variety of purposes, including to rule out medical causes of psychiatric symptoms, to record baseline data before prescribing medications that may lead to lab abnormalities, and to screen for general medical problems. What labs should we order for new patients?

Read More
Article

Laboratory Monitoring When Prescribing Psychotropics

Topics: Laboratory Testing in Psychiatry

When you are planning to start a patient on medications, what labs should you order at baseline, and what should you order over time? This is quite a different question from whether to do a set of labs at the start of treatment to screen for disease etiology, and it’s an area where I believe we should be much more proactive.

Read More
Expert QA

Pharmacogenetic Testing in Psychiatry

Topics: Laboratory Testing in Psychiatry

Dr. Perlis, can you help us understand the role of pharmacogenetics in psychiatric practice?

Read More
Research Update

Do SSRIs cause osteoporosis?

Topics: Antidepressants

A recent issue of Archives of Internal Medicine contained two articles suggesting that SSRIs may result in loss of bone density in the elderly.

Read More
Research Update

Lyrica (pregabalin) is approved for fibromyalgia

Fibromyalgia is a condition characterized by at least 3 months of widespread pain (both above and below the waist and on both sides of the body) and by the presence of at least 11 tender points (these are the official American College of Rheumatology criteria).

Read More
Research Update

Metaanalysis shows no difference between SSRIs and bupropion

Topics: Antidepressants

Clinical lore has it that SSRIs are preferable to bupropion for depressed patients who present with anxiety and insomnia. Papakostas and colleagues tested this assumption by obtaining patient data from 10 studies funded by GlaxoSmithKline (makers of brand name Wellbutrin) over the years.

Read More